Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Intensity Therapeutics, Inc. (INTS)
NASDAQ:INTS
RESEARCH TOOLSreports
Holding INTS?
Track your performance easily
INTS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.14 - $11.44
Previous Close$2.58
Volume38.04K
Average Volume (3M)13.92K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$2.78M
Total Debt (Recent Filing)$145.00K
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 13, 2025EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding13,867,697
10 Day Avg. Volume13,636
30 Day Avg. Volume13,916
Standard Deviation0.68
R-Squared0.08
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)14.75
Price to Sales (P/S)0.07
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$5.00Price Target Upside93.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Intensity Therapeutics, Inc. News
PremiumPre-Earnings
Is INTS a Buy, Before Earnings?
PremiumCompany Announcements
Intensity Therapeutics Shareholders Engage and Elect at Annual Meeting
Ownership Overview
16.15% Insiders
1.80% Mutual Funds
8.44% Other Institutional Investors
71.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
INTS FAQ
What was Intensity Therapeutics, Inc.’s price range in the past 12 months?
Intensity Therapeutics, Inc. lowest stock price was $2.14 and its highest was $11.44 in the past 12 months.
What is Intensity Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Intensity Therapeutics, Inc.’s upcoming earnings report date?
Intensity Therapeutics, Inc.’s upcoming earnings report date is Mar 13, 2025 which is in 109 days.
How were Intensity Therapeutics, Inc.’s earnings last quarter?
Intensity Therapeutics, Inc. released its earnings results on Nov 13, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.305 by $0.055.
Is Intensity Therapeutics, Inc. overvalued?
According to Wall Street analysts Intensity Therapeutics, Inc.’s price is currently Undervalued.
Does Intensity Therapeutics, Inc. pay dividends?
Intensity Therapeutics, Inc. does not currently pay dividends.
What is Intensity Therapeutics, Inc.’s EPS estimate?
Intensity Therapeutics, Inc.’s EPS estimate is -$0.23.
How many shares outstanding does Intensity Therapeutics, Inc. have?
Intensity Therapeutics, Inc. has 13,867,697 shares outstanding.
What happened to Intensity Therapeutics, Inc.’s price movement after its last earnings report?
Intensity Therapeutics, Inc. reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.305. Following the earnings report the stock price went up 2.581%.
Which hedge fund is a major shareholder of Intensity Therapeutics, Inc.?
Currently, no hedge funds are holding shares in INTS
---
Intensity Therapeutics, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (93.80% Upside)
$5.00 (93.80% Upside)
Blogger Sentiment
Bullish
INTS Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.22%
12-Months-Change
Fundamentals
Return on Equity
-173.98%
Trailing 12-Months
Asset Growth
-69.00%
Trailing 12-Months
Company Description
Intensity Therapeutics, Inc.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors.
---
INTS Stock 12 Month Forecast
Average Price Target
$5.00
▲(93.80% Upside)
Technical Analysis
Best Analysts Covering INTS
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-9.20%
reiterated a buy rating 3 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -9.20% per trade.
---